Detalhe da pesquisa
1.
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.
N Engl J Med
; 390(9): 783-794, 2024 Feb 29.
Artigo
Inglês
| MEDLINE | ID: mdl-38381664
2.
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
N Engl J Med
; 390(9): 795-805, 2024 Feb 29.
Artigo
Inglês
| MEDLINE | ID: mdl-37962077
3.
Dersimelagon in Erythropoietic Protoporphyrias.
N Engl J Med
; 388(15): 1376-1385, 2023 Apr 13.
Artigo
Inglês
| MEDLINE | ID: mdl-37043653
4.
Acute hepatic porphyrias - a guide for Hepatologists.
Hepatology
; 2024 Apr 12.
Artigo
Inglês
| MEDLINE | ID: mdl-38607698
5.
Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?
Hepatology
; 2024 Mar 22.
Artigo
Inglês
| MEDLINE | ID: mdl-38506926
6.
Sociodemographic and geographic differences in the US epidemiology of autoimmune hepatitis with and without cirrhosis.
Hepatology
; 77(2): 367-378, 2023 02 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35810446
7.
Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis.
Hepatology
; 2023 Dec 20.
Artigo
Inglês
| MEDLINE | ID: mdl-38117036
8.
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
Hepatology
; 78(2): 397-415, 2023 08 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37386786
9.
New Treatment Paradigms in Primary Biliary Cholangitis.
Clin Gastroenterol Hepatol
; 21(8): 2076-2087, 2023 07.
Artigo
Inglês
| MEDLINE | ID: mdl-36809835
10.
GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus.
Clin Gastroenterol Hepatol
; 21(7): 1902-1912.e13, 2023 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-36343847
11.
Application of the Latest Advances in Evidence-Based Medicine in Primary Biliary Cholangitis.
Am J Gastroenterol
; 118(2): 232-242, 2023 02 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36729104
12.
Setanaxib, a first-in-class selective NADPH oxidase 1/4 inhibitor for primary biliary cholangitis: A randomized, placebo-controlled, phase 2 trial.
Liver Int
; 43(7): 1507-1522, 2023 07.
Artigo
Inglês
| MEDLINE | ID: mdl-37183520
13.
Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one-year non-responders and predicts survival.
Liver Int
; 43(7): 1497-1506, 2023 07.
Artigo
Inglês
| MEDLINE | ID: mdl-37157905
14.
Impact on follow-up strategies in patients with primary sclerosing cholangitis.
Liver Int
; 43(1): 127-138, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35535655
15.
PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis.
BMC Gastroenterol
; 23(1): 75, 2023 Mar 15.
Artigo
Inglês
| MEDLINE | ID: mdl-36922785
16.
Evidence-based consensus guidelines for the diagnosis and management of erythropoietic protoporphyria and X-linked protoporphyria.
J Am Acad Dermatol
; 89(6): 1227-1237, 2023 12.
Artigo
Inglês
| MEDLINE | ID: mdl-36041558
17.
Efficacy and Safety of Bezafibrate Alone or in Combination with Ursodeoxycholic Acid in Primary Biliary Cholangitis: Systematic Review and Meta-Analysis.
Dig Dis Sci
; 68(4): 1559-1573, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36180756
18.
Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis.
Dig Dis Sci
; 68(3): 995-1005, 2023 03.
Artigo
Inglês
| MEDLINE | ID: mdl-35704252
19.
Response to Ursodeoxycholic Acid May Be Assessed Earlier to Allow Second-Line Therapy in Patients with Unresponsive Primary Biliary Cholangitis.
Dig Dis Sci
; 68(2): 514-520, 2023 02.
Artigo
Inglês
| MEDLINE | ID: mdl-35989386
20.
Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis.
J Hepatol
; 76(1): 75-85, 2022 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34487750